Immunotherapy effective in metastatic prostate cancers with specific markers of immune activation
University of Texas MD Anderson Cancer CenterA subset of patients with metastatic prostate cancer and specific markers of immune activity responded well to treatment with immune checkpoint inhibitors, according to results of a Phase II trial.